Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Nov 8, 2013)
  • 8-K (Oct 29, 2013)
  • 8-K (Oct 22, 2013)
  • 8-K (Oct 2, 2013)
  • 8-K (Sep 27, 2013)
  • 8-K (Sep 11, 2013)

 
Other

Allergan Finance LLC 8-K 2006

Documents found in this filing:

  1. 8-K
  2. 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant To Section 13 or 15(d) Of the Securities and Exchange Act Of 1934

 

May 4, 2006
Date of Report (Date of earliest event reported)

 

WATSON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

0-20045

 

95-3872914

(State or other Jurisdiction

 

(Commission File Number)

 

(IRS Employer

of Incorporation)

 

 

 

Identification Number)

 

 

 

 

 

311 Bonnie Circle

 

 

 

 

Corona, California

 

 

 

92880

(Address of principal executive

 

 

 

(Zip Code)

offices)

 

 

 

 

 

(951) 493-5300

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

Item 1.01                           Entry Into A Material Definitive Agreement.

 

On May 4, 2006, the Compensation Committee (the “Committee”) of the Board of Directors of Watson Pharmaceuticals, Inc. (the “Company”) adopted the 2006 Senior Executive Compensation Program (the “Program”). The terms of the Program are not contained in a formal written plan.

 

Pursuant to the Program and their current employment agreements, each senior executive (other than the Chief Executive Officer) of the Company (each, an “Executive Officer”) is eligible to receive an annual cash bonus targeted at, depending on his or her position with the Company, 35% to 45% of his or her base salary (the “Target Bonus”). Each Executive Officer’s annual cash bonus award may range from 0% to 150% of his or her Target Bonus, based upon (i) the Company achieving certain gross profit and/or operating cash flow targets (the “Financial Targets”), (ii) divisional contribution and divisional gross profit (where applicable) and (iii) the departmental and individual performance of such Executive Officer during 2006.

 

The application of the above factors in determining annual cash bonus awards varies by the position and division of the Executive Officer with the following ranges:

 

(i)                                     As applicable, from forty percent (40%) to sixty percent (60%) of the cash bonus award is based upon the Company’s actual performance against the Financial Targets,

 

(ii)                                  As applicable, from thirty percent (30%) to fifty percent (50%) of the cash bonus award is based on divisional contribution and divisional gross profit, and

 

(iii)                               As applicable, from thirty percent (30%) to forty percent (40%) of the cash bonus award is based on departmental and individual performance.

 

The Committee will determine whether and to what extent cash bonuses will be paid for fiscal year 2006 after the end of 2006.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated: May 10, 2006

WATSON PHARMACEUTICALS, INC.

 

 

 

 

 

By:

  /s/David A. Buchen

 

 

 

David A. Buchen

 

 

Senior Vice President, General Counsel

 

 

and Secretary

 

3


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki